Projects In Knowledge - Continuing Medical Education (CME)

Time 2020-12-09 18:03:21

Web Name: Projects In Knowledge - Continuing Medical Education (CME)

WebSite: http://www.projectsinknowledge.com

ID:128830

Keywords:

Knowledge,In,Projects,

Description:

Privacy Policy Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information. About this Privacy Policy www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional. Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as we or Projects In Knowledge, we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy. This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site. Privacy Policy Changes If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes. Information We Collect In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them. Information We Collect from Unregistered Visitors Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the referring URL ), the type of browser you use, the time and date of access, and other information that does not personally identify you. Information We Collect When You Register Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion. On our registration screens you will also find a Burning Question field. Submission of a Burning Question is completely voluntary. By submitting a Burning Question, you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations. Listserves When you are using a listserve or member-only discussion board on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not: Restrict or inhibit any other user from using the listserve Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder Post or transmit any information, software or other material which contains a virus or other harmful component Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions. Use of Cookies Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site. Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies. Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site remember you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you. Children's Privacy Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18. Uses We Make of Information In this section of our privacy policy, we identify the ways we may use information about you that we have collected. Aggregate Data We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes. Third Parties In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below. Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy. Protection of Information In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you. General Policies We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you. Projects In Knowledge Employees Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information. Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action. Privacy Questions or Concerns about Our Web Site For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com. Revision date: This policy was last updated on September 30, 2003. Multiple Myeloma ASH: Oral Regimen for Relapsed Multiple Myeloma Shows Promise BreakingMED An all-oral regimen for patients with relapsed multiple myeloma appears to improve progression-free survival and overall response when compared with historical outcomes, researchers reported at the 2020 virtual meeting of the American Society of Hematology. An all-oral regimen for patients with relapsed multiple myeloma appears to improve progression-free survival and overall response when compared with historical outcomes, researchers reported at the 2020 virtual meeting of the American Society of Hematology. Cancer Care Considerations A New Understanding for Existing Cancer Health Disparities Webcast Health disparities are receiving increasing attention. Despite many advances in cancer diagnosis and treatment, not everyone benefits from these advances. Join Dr. Christopher Flowers and Dr. Scarlett Gomez as they discuss existing racial/ethnic and socioeconomic disparities in cancer, social determinants of ... Health disparities are receiving increasing attention. Despite many advances in cancer diagnosis and treatment, not everyone benefits from these advances. Join Dr. Christopher Flowers and Dr. Scarlett Gomez as they discuss existing racial/ethnic and socioeconomic disparities in cancer, social determinants of health, and a model that considers health from the cell to society at large.more >> Cancer Care Considerations Targeting HER3 in Advanced NSCLC Webcast Human epidermal growth factor receptor 3 (HER3) is a member of the HER family of membrane proteins, and is overexpressed in up to 83% of non-small cell lung cancer (NSCLC) tumors. Overexpression of HER3 in NSCLC is associated with worse clinical outcomes. In this video presentation, Dr. Helena Yu discusses ... Human epidermal growth factor receptor 3 (HER3) is a member of the HER family of membrane proteins, and is overexpressed in up to 83% of non-small cell lung cancer (NSCLC) tumors. Overexpression of HER3 in NSCLC is associated with worse clinical outcomes. In this video presentation, Dr. Helena Yu discusses strategies to target HER3, including the recent promising results of a phase I trail of the antibody-drug conjugate (ADC) patritumab deruxtecan.more >> Multiple Myeloma Care of Patients With Relapsing/Refractory Multiple Myeloma After Multiple Prior Therapies: The Role of Newly Approved Antibody-Based Therapies @Point of CareChapter Two new antibody-based therapies, isatuximab and belantamab mafodotin, have recently been approved for the treatment of relapsed or refractory multiple myeloma (RRMM). Each occupies a unique line of therapy and provides a needed treatment option for your patients with RRMM. Join Noopur Raje, MD, as she ... Two new antibody-based therapies, isatuximab and belantamab mafodotin, have recently been approved for the treatment of relapsed or refractory multiple myeloma (RRMM). Each occupies a unique line of therapy and provides a needed treatment option for your patients with RRMM. Join Noopur Raje, MD, as she reviews the efficacy and safety of these new therapies and equips you to incorporate them into your practice. Throughout this activity you will find supportive multimedia hyperlinks that provide access to videos, journal articles, and other resources to enhance understanding of relevant issues.more >> Prostate Cancer Emerging Targeted Therapies in mCRPC: Focus on the PI3K/Akt/mTOR Pathway Webcast Over 90% of metastatic castration-resistant prostate cancers (mCRPC) harbor clinically actionable mutations, and one of the most common is loss of PTEN leading to activation of the Akt pathway. This loss has important prognostic implications because it is associated with worse response to treatment, relapse, ... Over 90% of metastatic castration-resistant prostate cancers (mCRPC) harbor clinically actionable mutations, and one of the most common is loss of PTEN leading to activation of the Akt pathway. This loss has important prognostic implications because it is associated with worse response to treatment, relapse, and early death. In this video presentation, Drs. Maha Hussain, Christopher Sweeney, and David VanderWeele discuss the current challenges in the treatment of mCRPC, review preclinical and clinical data supporting use of Akt-directed therapies in patients with mCRPC, and discuss emerging Akt inhibitors.more >> Cardiology Care Considerations Treatment of an Elderly Patient at High Risk for Stroke During the Covid-19 Pandemic CaseStudy The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients ... The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients with cardiac disease.more >> COPD Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD CaseStudy Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid (ICS) to LAMA and/or LABA therapy is informed by exacerbation history and eosinophil counts. Recently, single-inhaler LAMA/LABA/ICS triple therapies have become available. Clinical trial data show a benefit for triple therapy over LAMA/LABA or LABA/ICS treatment in patients with moderate/severe COPD. This case study follows a patient with newly diagnosed severe COPD. Factors to consider when assessing symptom burden, as well as nonpharmacologic and pharmacologic treatment options, are discussed.more >> Breast Cancer Considerations for CDK4/6 Inhibitors in the Neoadjuvant and Adjuvant Settings of Hormone Receptor-Positive Breast Cancer Webcast This activity involves a discussion about the ongoing adjuvant clinical trials of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. Key differences ... This activity involves a discussion about the ongoing adjuvant clinical trials of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. Key differences across studies as well as recent results are also discussed.more >> Parkinson's Disease Journal Club Podcast in Neurology Podcast In this Journal Club podcast our experts discuss a paper published in the Journal of Clinical Medicine that looked at the impact of Covid-19 on patients with Parkinson’s disease—physically, emotionally, and how they are keeping up with their treatments. In this Journal Club podcast our experts discuss a paper published in the Journal of Clinical Medicine that looked at the impact of Covid-19 on patients with Parkinson’s disease—physically, emotionally, and how they are keeping up with their treatments. Heart Failure AHA: The Funder Pulled Out, But Sotagliflozin Trials May Pull Off a Surprising Win BreakingMED A pair of trials of a novel inhibitor of sodium-glucose cotransporter 1 and 2 (SGLT1/2i) offer the first tantalizing hint of a treatment that appears to demonstrate efficacy not only for reduced ejection fraction heart failure (HFrEF) but also for preserved ejection fraction heart failure (HFpEF). Both trials ... A pair of trials of a novel inhibitor of sodium-glucose cotransporter 1 and 2 (SGLT1/2i) offer the first tantalizing hint of a treatment that appears to demonstrate efficacy not only for reduced ejection fraction heart failure (HFrEF) but also for preserved ejection fraction heart failure (HFpEF). Both trials were published online in The New England Journal of Medicine and presented at the American Heart Association’s virtual Scientific Sessions 2020.more >> State of the Science: Multiple Sclerosis Innovations State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from ... State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from peer-reviewed scientific journals. This program is designed to provide timely, scientific data that can be applied directly to the clinical settings for in-the-trenches clinicians. more >> Master Class: Chronic Lymphocytic Leukemia Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case ... Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case studies utilizing current and emerging therapies based on the most up-to-date evidence-based medicine, and review of articles from peer-reviewed scientific journals. Modules cover the role of minimal residual disease in guiding treatment decisions for patients on targeted therapies, such as ibrutinib and venetoclax, and treatment considerations for patients with ibrutinib-refractory CLL, including the role of venetoclax and emerging agents in this difficult-to-treat population. more >> The Art & Science of Heart Failure Management The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure ... The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure management. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the European Society of Cardiology (ESC) Congress 2017, the Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting, the American Heart Association (AHA) Scientific Sessions, and the American College of cardiology's (ACC) 67th Annual Scientific Sessions & Expo and poster presentations from the Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting and the American College of cardiology's (ACC) 67th Annual Scientific Sessions & Expo.more >> Pulmonology Mastery in COPD Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes ... Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the ATS (American Thoracic Society) 2017 Meeting, the ERS (European Respiratory Society) International Congress 2017, and CHEST (American College of Chest Physicians) Annual Meeting and poster presentations from CHEST (American College of Chest Physicians) Annual Meeting.more >> Mastery of Medicine in Diabetes Management Mastery of Medicine in Diabetes Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in diabetes ... Mastery of Medicine in Diabetes Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in diabetes management. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the Endocrine Society's 99th Annual Meeting & Expo, the American Association of Clinical Endocrinologists 26th Annual Scientific and Clinical Congress, and the American Diabetes Association 77th Scientific Sessions, poster presentations offering audio/video of presenters, downloadable PDF copies of posters, full transcripts of presentations, noted expert summations of key takeaways, and clinical applications; and clinical conversation video roundtable.more >> Clinical Context: Stroke Prevention in Atrial Fibrilation Clinical Context: Stroke Prevention in Atrial Fibrillation is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.The curriculum includes:6 case studiesMedPage Today meeting ... Clinical Context: Stroke Prevention in Atrial Fibrillation is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.The curriculum includes:6 case studiesMedPage Today meeting coverage that will report on cutting-edge news as it breaks from the European Society of Cardiology (ESC) Congress 2015, Transcatheter Cardiovascular Therapeutics (TCT) 2015, American Heart Association Scientific Sessions 2015 (Nov.), International Stroke Conference 2016, and the American College of Cardiology (ACC) 65th Annual Scientific Session & Expo (2016)Activities based on new and emerging data from studies published in peer-reviewed journalsHallway buzz segments with videomore >> Hematology Mastery in Multiple Myeloma Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. ... Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the 2017 ASCO (American Society of Clinical Oncology) Annual Meeting, the Society of Hematologic Oncology (SOHO) Annual Meeting, and ASH 2017 – The 59th American Society of Hematology Annual Meeting and Exposition and poster presentations from ASH 2017 – The 59th American Society of Hematology Annual Meeting and Exposition. more >> Rheumatology Mastery in Rheumatoid Arthritis Rheumatology Mastery in Rheumatoid Arthritis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid ... Rheumatology Mastery in Rheumatoid Arthritis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid arthritis. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the British Society for Rheumatology (BSR) 2017 and poster presentations offering audio/video of presenters, downloadable PDF copies of posters, full transcripts of presentations, noted expert summations of key takeaways, and clinical applications.more >> Neurology Mastery in Multiple Sclerosis Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. ... Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the American Neurological Association (ANA) 141st Annual Meeting, the Society for Neuroscience (SfN) 46th Annual Meeting, the American Academy of Neurology (AAN) 68th Annual Meeting, and the Consortium of Multiple Sclerosis Centers (CMSC) 31st Annual Meeting and poster presentations from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the American Academy of Neurology (AAN) 68th Annual Meeting. more >> Rheumatology Mastery In Ankylosing Spondylitis Rheumatology Mastery in Ankylosing Spondylitis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in ankylosing ... Rheumatology Mastery in Ankylosing Spondylitis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in ankylosing spondylitis. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the British Society for Rheumatology (BSR) 2017 and European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology 2017 and poster presentations offering audio/video of presenters, downloadable PDF copies of posters, full transcripts of presentations, noted expert summations of key takeaways, and clinical applications.more >> Ovarian Cancer @Point of Care Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly. Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly. Pulmonary Arterial Hypertension @Point of Care Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically for PAH, epoprostenol. Since that time the FDA has approved a dozen more agents for PAH, so there are now 13 FDA-approved PAH therapeutics. More available treatments have not, however, shortened the time to diagnosis, which still averages 24 months. Nonetheless, there have been significant changes in recommended treatment regimens, with a shift from monotherapy to initial or sequential combination therapy. Utilizing insights from top specialists in the field as well as hyperlinks to videos, journal articles, and case reports this activity provides an overview of the PAH clinical and research landscape, including discussion of anticipated guideline updates. more >> Bipolar Disorder @Point of Care Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and approved for the treatment of the various phases of this disorder. The Bipolar Disorder @Point of Care platform provides a comprehensive and current understanding of the diagnostic criteria for assessment of bipolar disorder, standard-of-care treatment recommendations, and strategies to improve adherence and patient outcomes organized into a progressive series of chapters and patient cases with up-to-date information. The program utilizes insights from top specialists in the field, as well as providing hyperlinks to videos, journal articles, and other external resources, to enhance your understanding of pertinent issues involved in the diagnosis and treatment of bipolar disorder to help with the development of effective treatment plans so that best outcomes can be achieved.more >> Classical Hodgkin Lymphoma @Point of Care Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL now include interim PET imaging, an evolving use of radiotherapy, and the option of brentuximab vedotin, newly approved for use in this setting. Patients with relapsed or refractory CHL have typically been treated with the decades-old strategy of second-line systemic therapy followed by high-dose therapy and autologous stem cell transplant. Recently, however, therapies targeted to the unique biology of the disease, including brentuximab vedotin, nivolumab, and pembrolizumab, have been approved for use and expand the options for improved outcomes in these patients.more >> Nontuberculous Mycobacterial Lung Disease @Point of Care Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment regimens, and complex treatments of long duration that are prone to adverse effects and toxicity, there is a significant unmet need to improve the care and outcomes of patients with NTM lung disease. The Nontuberculous Mycobacterial Lung Disease @Point of Care platform delivers a comprehensive understanding of NTM risk factors, diagnosis, best practices for treatment strategy, and optimal patient management by incorporating practical guidance and insights from experts. Throughout this program you will find supportive multimedia hyperlinks that provide access to videos, journal articles, and other resources to enhance understanding of relevant issues.more >> Heart Failure @Point of Care Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are inconsistently applied to both hospitalized and ambulatory patients. The Heart Failure @Point of Care platform examines the presentation and diagnosis of heart failure, guideline-directed medical management of heart failure with up-to-date scientific data and clinical trial results, and insights from top specialists. Features of this program include: comprehensive and current information organized into a progressive series of chapters and patients cases, with practical guidance and insights from heart failure experts along with hyperlinks to videos, journal articles, and other external resources to enhance your understanding of the relevant issues. more >> Alzheimer's Disease @Point of Care This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD. This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD. Atopic Dermatitis @Point of Care Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With the increasing number of disease-modifying therapies available, it is important for patients to be accurately diagnosed and receive appropriate assessment of their disease severity. The Atopic Dermatitis @Point of Care platform provides a comprehensive understanding of the current diagnostic and treatment landscape for AD organized into a progressive series of activities that incorporate insights from top specialists in the field and include hyperlinks to videos, journal articles, and other external resources to enhance understanding of the relevant issues. The overall program highlights guideline- and evidence-based diagnostic and treatment strategies to help clinicians formulate effective treatment plans and optimize outcomes for patients with AD.more >> Hepatocellular Carcinoma @Point of Care This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of patients with hepatocellular carcinoma.more >> Prostate Cancer Emerging Targeted Therapies in mCRPC: Focus on the PI3K/Akt/mTOR Pathway Webcast Over 90% of metastatic castration-resistant prostate cancers (mCRPC) harbor clinically actionable mutations, and one of the most common is loss of PTEN leading to activation of the Akt pathway. This loss has important prognostic implications because it is associated with worse response to treatment, relapse, ... Over 90% of metastatic castration-resistant prostate cancers (mCRPC) harbor clinically actionable mutations, and one of the most common is loss of PTEN leading to activation of the Akt pathway. This loss has important prognostic implications because it is associated with worse response to treatment, relapse, and early death. In this video presentation, Drs. Maha Hussain, Christopher Sweeney, and David VanderWeele discuss the current challenges in the treatment of mCRPC, review preclinical and clinical data supporting use of Akt-directed therapies in patients with mCRPC, and discuss emerging Akt inhibitors.more >> Cancer Care Considerations A New Understanding for Existing Cancer Health Disparities Webcast Health disparities are receiving increasing attention. Despite many advances in cancer diagnosis and treatment, not everyone benefits from these advances. Join Dr. Christopher Flowers and Dr. Scarlett Gomez as they discuss existing racial/ethnic and socioeconomic disparities in cancer, social determinants of ... Health disparities are receiving increasing attention. Despite many advances in cancer diagnosis and treatment, not everyone benefits from these advances. Join Dr. Christopher Flowers and Dr. Scarlett Gomez as they discuss existing racial/ethnic and socioeconomic disparities in cancer, social determinants of health, and a model that considers health from the cell to society at large.more >> Cardiology Care Considerations Treatment of an Elderly Patient at High Risk for Stroke During the Covid-19 Pandemic CaseStudy The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients ... The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients with cardiac disease.more >> Cancer Care Considerations Targeting HER3 in Advanced NSCLC Webcast Human epidermal growth factor receptor 3 (HER3) is a member of the HER family of membrane proteins, and is overexpressed in up to 83% of non-small cell lung cancer (NSCLC) tumors. Overexpression of HER3 in NSCLC is associated with worse clinical outcomes. In this video presentation, Dr. Helena Yu discusses ... Human epidermal growth factor receptor 3 (HER3) is a member of the HER family of membrane proteins, and is overexpressed in up to 83% of non-small cell lung cancer (NSCLC) tumors. Overexpression of HER3 in NSCLC is associated with worse clinical outcomes. In this video presentation, Dr. Helena Yu discusses strategies to target HER3, including the recent promising results of a phase I trail of the antibody-drug conjugate (ADC) patritumab deruxtecan.more >> COPD Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD CaseStudy Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid (ICS) to LAMA and/or LABA therapy is informed by exacerbation history and eosinophil counts. Recently, single-inhaler LAMA/LABA/ICS triple therapies have become available. Clinical trial data show a benefit for triple therapy over LAMA/LABA or LABA/ICS treatment in patients with moderate/severe COPD. This case study follows a patient with newly diagnosed severe COPD. Factors to consider when assessing symptom burden, as well as nonpharmacologic and pharmacologic treatment options, are discussed.more >> Breast Cancer Considerations for CDK4/6 Inhibitors in the Neoadjuvant and Adjuvant Settings of Hormone Receptor-Positive Breast Cancer Webcast This activity involves a discussion about the ongoing adjuvant clinical trials of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. Key differences ... This activity involves a discussion about the ongoing adjuvant clinical trials of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. Key differences across studies as well as recent results are also discussed.more >> Parkinson's Disease Journal Club Podcast in Neurology Podcast In this Journal Club podcast our experts discuss a paper published in the Journal of Clinical Medicine that looked at the impact of Covid-19 on patients with Parkinson’s disease—physically, emotionally, and how they are keeping up with their treatments. In this Journal Club podcast our experts discuss a paper published in the Journal of Clinical Medicine that looked at the impact of Covid-19 on patients with Parkinson’s disease—physically, emotionally, and how they are keeping up with their treatments. HIV Ask the Experts: Selecting the Right ART for the Right Person at the Right Time Webcast This activity involves a discussion about the practical clinical management and maintenance of persons living with human immunodeficiency virus (HIV), including recent data about two key issues involved with antiretroviral therapy (ART) decision making: pregnancy and weight gain. In addition, strategies for ... This activity involves a discussion about the practical clinical management and maintenance of persons living with human immunodeficiency virus (HIV), including recent data about two key issues involved with antiretroviral therapy (ART) decision making: pregnancy and weight gain. In addition, strategies for counseling PLWH and for optimizing ART are discussed.more >> Breast Cancer Approved CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Breast Cancer Webcast This activity involves a discussion about the evidence base for the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6) in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. In addition, ... This activity involves a discussion about the evidence base for the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6) in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. In addition, strategies for individualizing treatment with CDK4/6 inhibitors are discussed.more >> Cancer Care Considerations Journal Club Podcast in Oncology Podcast In this Journal Club podcast, our experts discuss the findings of a study published in Lancet Oncology that suggests Covid-19 appears to have a different trajectory for patients depending on the type of cancer that they have. Patients with hematologic cancers—leukemia, lymphoma, myeloma—developed more severe ... In this Journal Club podcast, our experts discuss the findings of a study published in Lancet Oncology that suggests Covid-19 appears to have a different trajectory for patients depending on the type of cancer that they have. Patients with hematologic cancers—leukemia, lymphoma, myeloma—developed more severe Covid-19 compared with those with solid tumors.more >> Cardiology Care Considerations Treatment of an Elderly Patient at High Risk for Stroke During the Covid-19 Pandemic CaseStudy The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients ... The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients with cardiac disease.more >> COPD Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD CaseStudy Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid (ICS) to LAMA and/or LABA therapy is informed by exacerbation history and eosinophil counts. Recently, single-inhaler LAMA/LABA/ICS triple therapies have become available. Clinical trial data show a benefit for triple therapy over LAMA/LABA or LABA/ICS treatment in patients with moderate/severe COPD. This case study follows a patient with newly diagnosed severe COPD. Factors to consider when assessing symptom burden, as well as nonpharmacologic and pharmacologic treatment options, are discussed.more >> Heart Failure Patient With Worsening HFrEF and Multiple Hospitalizations CaseStudy Patients with heart failure (HF) with reduced ejection fraction should be managed using guideline-directed medical therapy, which includes agents that block the renin-angiotensin system, such as angiotensin converting enzymes inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin ... Patients with heart failure (HF) with reduced ejection fraction should be managed using guideline-directed medical therapy, which includes agents that block the renin-angiotensin system, such as angiotensin converting enzymes inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors. However, even with optimal therapy, many patients eventually decompensate. This case illustrates the real-life clinical scenario of a patient who has multiple hospitalizations for decompensation, illustrating the use of shared decision making to optimize treatment for HF and emphasizing the importance of enrollment in clinical trials investigating new agents for the treatment of HF, in this case vericiguat.more >> Ovarian Cancer Combination First-Line Maintenance Therapy in Ovarian Cancer CaseStudy The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as ... The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as first-line maintenance therapy for advanced ovarian cancer. Join Dr. Leslie Randall as she describes a case in which a PARP inhibitor is added to bevacizumab as first-line maintenance for a patient with advanced ovarian cancer.more >> Heart Failure Patient With Worsening HFrEF and Prediabetes CaseStudy Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy, and include use of agents that modulate all pathways known to affect HF outcomes. This includes evidence-based beta blockers and agents that inhibit the renin-angiotensin-aldosterone ... Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy, and include use of agents that modulate all pathways known to affect HF outcomes. This includes evidence-based beta blockers and agents that inhibit the renin-angiotensin-aldosterone system, such as the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan. More recently, sodium-glucose cotransporter 2 inhibitors have also been shown to improve outcomes in all HFrEF patients, regardless of the presence or absence of comorbid diabetes. This case illustrates the real-life clinical scenario of a patient with multiple cardiovascular risk factors, illustrating the use of shared decision making to optimize treatment for HF, which includes use of all known agents that improve morbidity and mortality.more >> Asthma Case Study: Investigational Single-Inhaler Triple Therapy for Uncontrolled Asthma CaseStudy Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics ... Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics targeting type 2 inflammation, 30% to 35% of uncontrolled severe asthmatics for whom biologics are either not an option or not effective require additional therapeutic options. These difficult-to-treat patients also have the option of an add-on long-acting muscarinic antagonist (LAMA) bronchodilator; however, this requires an additional inhaler device, complicating treatment regimens. This case follows a 53-year-old woman with uncontrolled moderate to severe asthma that has multiple triggers and causes, including allergic and nonallergic. Add-on LAMA treatment is discussed with the patient, as are clinical trials of add-on LAMA treatment in single-inhaler devices with ICS/LABA combinations. The benefits of enrollment in a clinical trial are also discussed.more >> Asthma Case Study: Management of a Patient With Severe Eosinophilic Asthma CaseStudy Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, and IL-13, is the most common pathogenetic mechanism in severe asthma. Type 2 inflammation is often associated with varying degrees of blood and sputum eosinophilia. For patients with severe eosinophilic asthma without a significant allergic component, four biologic medications are now available. This case study follows a 48-year-old man with asthma onset in his 40s whose eosinophilic asthma is now uncontrolled despite optimal treatment. The choice of a biologic for such a patient can be influenced by a number of factors. The case highlights some of these factors and details the clinical data supporting the use of these treatments.more >> Metastatic Melanoma Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma CaseStudy Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse events. For metastatic melanoma patients with a BRAF V600 mutated tumor, combination targeted therapy with BRAF and MEK inhibitors is also an option. Because immunotherapy is associated with immune-related adverse events that can resemble autoimmune disease, pre-existing autoimmune disease can further complicate the treatment choice. This case study follows a 54-year-old man with metastatic melanoma and pre-existing rheumatoid arthritis. The patient’s tumor is BRAF V600 mutated and PD-L1 expression negative. The case explores the patient’s treatment options, which include combination immunotherapy.more >> Heart Failure Optimizing Treatment for a Patient With Hypertension and HFrEF CaseStudy Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who ... Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who develops heart failure after years of uncontrolled hypertension, and who remains symptomatic even after initial treatment of her disease. It highlights important considerations for both the diagnosis and initial treatment of heart failure, then illustrates use of recent clinical trial outcomes and GDMT for further management optimization.more >> Multiple Sclerosis Managing RRMS Patient who Converted to SPMS CaseStudy This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in ... This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in recent years for the treatment of progressive forms of MS.more >> We appreciate our customers and hold ourselves to the highest privacy standards. Access My Information or Delete My Information

TAGS:Knowledge In Projects 

<<< Thank you for your visit >>>

Hot Websites